Our data show that ACE2 enzymatic activity is a potential therapeutic strategy to alleviate the symptoms of acute lung pathologies in COVID-19 patients, further warranting the significance of specific molecular targeting in treating COVID-19. Here, ACE2 is linked to COVID-19.